Search results for "ExAC"

showing 10 items of 1440 documents

Pharmacotherapy of COPD in Central and Eastern Europe - The POPE study

2016

Introduction: In Central and Eastern Europe (CEE) the burden of chronic obstructive pulmonary disease (COPD) is high. It remains unknown whether patients are treated in line with GOLD recommendations or according to their phenotypes. Our aim was to analyze the treatment patterns of COPD in CEE. Methods: In the frame of the POPE study (ClinicalTrials.gov - NCT02119494) data including pharmacotherapy were collected in patients with stable COPD across 11 CEE countries. Results: 3366 patients (66±9 yrs, 70% male, FEV 1 53±18%) participated in the study. In all GOLD categories, the most widely used medications were long-acting beta-2 agonists (LABA), followed by long-acting antimuscarinic agents…

medicine.medical_specialtyCOPDbiologyExacerbationbusiness.industryPulmonary diseaseInhaled corticosteroidsOverlap syndromeLamabiology.organism_classificationmedicine.disease3. Good health03 medical and health sciences0302 clinical medicinePharmacotherapy030228 respiratory systemInternal medicinePhysical therapyMedicineIn patient030212 general & internal medicinebusinesshormones hormone substitutes and hormone antagonists1.12 Clinical Problems - COPD
researchProduct

Granulocyte–Macrophage Colony-Stimulating Factor in the Therapy of Adults with De Novo Acute Myeloblastic Leukemia: An Update of a Double-Blind Rando…

1997

We investigated whether granulocytemacrophage colony-stimulating factor (GMCSF) given concomitantly with chemotherapy (CT) improves the outcome of adults with de novo acute myeloblastic leukemia (AML) by increasing the efficacy of CT and reducing infections. CT included cytarabine (ara-C) daunorubicin, and etoposide (DAV) for induction and early consolidation therapy and one cycle with high-dose (patients aged ≤50 years) or intermediate-dose ara-C (patients aged >50 years) /daunorubicin for late consolidation therapy. Eighty patients were randomized after DAV 1 to receive either GM-CSF (Escherichia coli, 250 µg/m2 per day, s.c.) or placebo starting 48 h prior to DAV II and the subsequent co…

medicine.medical_specialtyChemotherapybusiness.industrymedicine.medical_treatmentPlacebo-controlled studyPlaceboGastroenterologyExact testMedian follow-upInternal medicineCytarabinemedicineAbsolute neutrophil countPhysical therapybusinessEtoposidemedicine.drug
researchProduct

Fluticasone propionate/formoterol: a fixed-combination therapy with flexible dosage.

2014

International guidelines describe asthma control as the main outcome of asthma management. Prevention of symptoms, improved quality of life, and reduction of exacerbations are the main components, consequently decreasing health care costs. However, many of these objectives remain unmet in real life: several surveys show that a large proportion of asthmatic patients are not well controlled despite the efficacy of current available treatment. Several randomized controlled clinical trials indicate that combining inhaled corticosteroids and long-acting β2-agonists, by means of a single inhaler, greatly improves the management of the disease. The results of 9 multicenter phase III clinical studi…

medicine.medical_specialtyCombination therapyAsthma exacerbationSettore MED/10 - Malattie dell'Apparato RespiratorioSettore MED/10 - Malattie Dell'Apparato RespiratorioFluticasone propionateAsthma control; Asthma exacerbations; Fixed-combination therapy; Fluticasone propionate/formoterol; Single-aerosol inhalerAsthma controlFluticasone propionate/formoterolForced Expiratory VolumeFormoterol FumarateInternal MedicineMedicineHumansAnti-Asthmatic AgentsAsthma exacerbationsParticle SizeIntensive care medicineAsthmaFluticasonebusiness.industryInhalerNebulizers and VaporizersFixed-combination therapyAsthma control; Asthma exacerbations; Fixed-combination therapy; Fluticasone propionate/formoterol; Single-aerosol inhaler; Androstadienes; Anti-Asthmatic Agents; Asthma; Bronchodilator Agents; Drug Combinations; Ethanolamines; Fluticasone; Forced Expiratory Volume; Formoterol Fumarate; Humans; Nebulizers and Vaporizers; Particle Size; Quality of Life; Treatment Outcomemedicine.diseaseSingle-aerosol inhalerAsthmaBronchodilator AgentsAndrostadienesDrug CombinationsTreatment OutcomeTolerabilityAsthma control Asthma exacerbations Fixed-combination therapy Fluticasone propionate/formoterol Single-aerosol inhalerEthanolaminesAnesthesiaAsthma exacerbations; Asthma control; Fixed-combination therapy; Fluticasone propionate/formoterol; Single-aerosol inhalerQuality of LifeFluticasoneFormoterol FumarateFormoterolbusinessmedicine.drugEuropean journal of internal medicine
researchProduct

The spectrum of risk factors for contrast induced nephropathy in patients undergoing coronary angiography or intervention

2014

Abstract Introduction Contrast induced nephropathy is an unfavorable acute event which can complicate the clinical course of patients undergoing coronary angiography. Clinical characteristics predisposing to its occurrence are still rather obscure. Methods We enrolled 591 patients (mean age 64.2 ± 10.98; 449 male and 142 female) who underwent emergency or elective Coronary angiography/Angioplastic in our Cardiologic Division between 10/2006 and 06/2008, paying attention to their Cardiovascular risk factors, dose and type of contrast medium, type and number of affected coronary arteries, pharmacological therapies, baseline renal function and extracoronary atherosclerosis. We performed a univ…

medicine.medical_specialtyCreatininebusiness.industryContrast-induced nephropathyRenal functionFibrinogenmedicine.diseaseCoronary arteriessymbols.namesakeContrast mediumchemistry.chemical_compoundmedicine.anatomical_structurechemistryInternal medicineDiabetes mellitusmedicineCardiologysymbolsbusinessFisher's exact testmedicine.drugJournal of Indian College of Cardiology
researchProduct

Occurrence and timing of complications following traumatic dental injuries: A retrospective study in a dental trauma department

2016

Background This study explores the pattern of complications occurrence resulting from traumatic dental injuries, the relation of this pattern to the number of years from the time of the injury to its first diagnosis, and other contributing characteristics such as root development and trauma characteristic. Material and Methods Patients’ data treated following dental trauma from 2002 to 2014 were classified and grouped according to age, gender, tooth type, injury type, diagnosis and the time that elapsed between the traumatic event and the diagnosis of complications (TIC). The distribution function of the quantitative parameters was determined with the Kolmogorov-Smirnov test. Fisher exact t…

medicine.medical_specialtyDentistryOdontologíaOperative Dentistry and EndodonticsAvulsion030207 dermatology & venereal diseases03 medical and health sciencessymbols.namesake0302 clinical medicinestomatognathic systemmedicineMaxillary central incisorGeneral DentistryFisher's exact testPulp necrosisDental traumabusiness.industryResearchRetrospective cohort study030206 dentistrymedicine.diseaseCiencias de la saludSurgerystomatognathic diseasesTraumatic injurysymbolsUNESCO::CIENCIAS MÃ DICAS:CIENCIAS MÃ DICAS [UNESCO]businessComplicationJournal of Clinical and Experimental Dentistry
researchProduct

Evaluating the neurotoxic effects of lactational exposure to persistent organic pollutants (POPs) in Spanish children.

2012

Although the brain continues developing in the postnatal period, epidemiological studies on the effects of postnatal exposure to neurotoxic POPs through breast-feeding remain mostly inconclusive. Failure to detect associations between postnatal exposure and health outcomes may stem from the limitations of commonly employed approaches to assess lactational exposure. The aim of the present study was to assess whether lactational exposure to polychlorinated biphenyl-153 (PCB-153), dichlorodiphenyldichloroethylene (DDE), or hexachlorobenzene (HCB) as estimated with a physiologically based pharmacokinetic (PBPK) model, is associated with decrements in mental and psychomotor development scores of…

medicine.medical_specialtyDichlorodiphenyl DichloroethyleneBreastfeedingPhysiologyNeuropsychological TestsToxicologyBayley Scales of Infant DevelopmentModels BiologicalRisk AssessmentDevelopmental psychologychemistry.chemical_compoundChild DevelopmentCognitionPregnancyRisk FactorsEpidemiologymedicineHexachlorobenzeneHumansLactationPsychomotor learningPregnancyMilk Humanbusiness.industryGeneral NeuroscienceAge FactorsInfant NewbornBrainInfantHexachlorobenzenemedicine.diseasePolychlorinated BiphenylsBreast FeedingchemistryDichlorodiphenyldichloroethyleneMaternal ExposureSpainPrenatal Exposure Delayed EffectsLinear ModelsPopulation studyEnvironmental PollutantsFemaleNeurotoxicity SyndromesbusinessPsychomotor PerformanceNeurotoxicology
researchProduct

Psoriasis: Embarking a dynamic shift in the skin microbiota

2021

Recent interest has arisen regarding the role of microbiome and its composition in the pathogenesis of psoriasis. Numerous studies have shown that there are alterations in skin flora arrangement between normal individuals and psoriatic patients. Psoriasis exacerbation could be interconnected with epidermal or mucosal colonization with streptococci, Malassezia, Staphylococcus aureus, or Candida albicans. The role of cutaneous and gut microbiome in psoriasis pathogenesis has recently been studied in both human and animal models. In this review, we try to evaluate various pathogenic mechanisms linking the microbiota and psoriasis. The literature research included peer-reviewed articles which i…

medicine.medical_specialtyExacerbation610 MedizinMEDLINESkin floraDermatology030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicine610 Medical sciencesPsoriasisCandida albicansmedicineAnimalsHumansPsoriasisMicrobiomeCandida albicansSkinMalasseziabiologybusiness.industryMicrobiotabiology.organism_classificationmedicine.diseaseDermatologyClinical trial030220 oncology & carcinogenesisMalasseziabusinessJournal of Cosmetic Dermatology
researchProduct

Cost-effectiveness of switching from omalizumab to mepolizumab in uncontrolled severe eosinophilic asthma

2020

Background: Severe asthma is burdened by frequent exacerbations and use of oral corticosteroids (OCS) which worsen patients’ quality of life and increased healthcare spending. Objectives: To assess the clinical and economic impact of switching from omalizumab (OMA) to mepolizumab (MEP) in patients eligible for both biologics but not optimally controlled with OMA. Methods: Uncontrolled patients referred to 6 asthma clinics in south of Italy switched from OMA to MEP, were enrolled and followed-up to Jan 2020. Clinical information included blood eosinophil count, asthma control test (ACT), pulmonary function, IgE, exhaled nitric oxide (FeNO), OCS intake, drugs, exacerbations/hospitalizations, …

medicine.medical_specialtyExacerbationCost effectivenessbusiness.industryOmalizumabmedicine.diseaseDiscontinuationPulmonary function testingInternal medicineExhaled nitric oxidemedicinebusinessMepolizumabmedicine.drugAsthmaEthics and economics
researchProduct

A 2013 European survey of clinical practice patterns in the management of Graves' disease

2014

SummaryObjective Management of Graves' disease (GD) in Europe was published in 1987. Aim of this survey was to provide an update on clinical practice in Europe, and to compare it with a 2011 American survey. Design Members of the European Thyroid Association (ETA) were asked to participate in a survey on management of GD, using the same questionnaire of a recent American survey. Results A total of 147 ETA members participated. In addition to serum TSH and free T4 assays, most respondents would request TSH-receptor autoantibody (TRAb) measurement (85·6%) and thyroid ultrasound (70·6%) to confirm aetiology, while isotopic studies were selected by 37·7%. Antithyroid drug (ATD) therapy was the …

medicine.medical_specialtyExacerbationEndocrinology Diabetes and MetabolismGraves' diseaseThyrotropin030209 endocrinology & metabolismTrabDisease03 medical and health sciences0302 clinical medicineEndocrinologyAntithyroid AgentsPregnancySurveys and QuestionnairesInternal medicinemedicineHumansPractice Patterns Physicians'AutoantibodiesPregnancyMethimazolebusiness.industryThyroidReceptors Thyrotropinmedicine.diseaseGraves DiseaseEuropePregnancy ComplicationsThyroxineEndocrinologymedicine.anatomical_structurePropylthiouracil030220 oncology & carcinogenesisNorth AmericaEtiologyFemalePropylthiouracilbusinessmedicine.drugClinical Endocrinology
researchProduct

Impact of domestic mould exposure on Aspergillus biomarkers and lung function in patients with chronic obstructive pulmonary disease

2021

International audience; Patients with chronic obstructive pulmonary disease (COPD) are frequently colonised or sensitised by Aspergillus, but clinical significance remains unclear. Furthermore, little is known on the impact of indoor mould exposure during COPD. In this study, we assessed the relationship between domestic mould exposure, Aspergillus biomarkers and COPD severity during acute exacerbation and at stable state. Aspergillus section Fumigati culture in sputum and anti-Aspergillus antibodies detection (IgG and precipitins) were followed up in COPD patients that were prospectively recruited during exacerbation (n = 62), and underwent a visit at stable state after 18 months (n = 33).…

medicine.medical_specialtyExacerbationMESH: Pulmonary Disease Chronic Obstructive010501 environmental sciencesEnvironmentMESH: Forced Expiratory VolumeAspergillosis01 natural sciencesBiochemistryGastroenterologyPulmonary Disease Chronic Obstructive03 medical and health sciences0302 clinical medicineanti-Aspergillus antibodiesForced Expiratory VolumeInternal medicinemedicineAspergillosisHumansCOPDClinical significanceMESH: Lung030212 general & internal medicineMESH: AspergillosisLungLung function0105 earth and related environmental sciencesGeneral Environmental Science[SDV.EE.SANT]Life Sciences [q-bio]/Ecology environment/HealthCOPDAspergillusMESH: Humansbiologybusiness.industryFungimedicine.diseasebiology.organism_classificationrespiratory tract diseasesAspergillusMESH: Aspergillusbiology.proteinMESH: BiomarkersSputummedicine.symptomAntibodybusinessBiomarkers
researchProduct